Good announcement which within the finer details reinforces a lot of potential for the future.
“Interest in the new kit is growing within Australian laboratories. Several domestic private and public testing laboratories are already using the EasyScreenTM Respiratory Pathogen Detection Kit and this new kit can be used alone or alongside the broader respiratory kit which detects 14 common respiratory pathogens. Genetic Signatures’ current customers have already incorporated the new EasyScreenTM SARS-CoV-2 Detection Kit into their testing programs as have several new customers, and discussions are underway with other domestic laboratories who have expressed interest in the kits.
Be no shortage of new and prospective clients in the near future. Surprised people selling on the back of this down to previous closing price. Long term prospects very very good
GSS Price at posting:
$1.89 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)